Insider Trading activities of Lexicon Pharmaceuticals, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Lexicon Pharmaceuticals, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Lexicon Pharmaceuticals, Inc. since year 2005. Table 2 shows the detailed insider transactions of Lexicon Pharmaceuticals, Inc. since 2005. The reporting company's ticker symbol is LXRX. The reporting company's CIK number is 1062822.
The total value of stock buying since 2005 is $496,557,301.
The total value of stock sales since 2005 is $1,274,474.
The total value of stock option exercises since 2005 is $871,402.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Lexicon Pharmaceuticals, Inc. (LXRX).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-11 768,673 $7,499,294 0 $0 0 $0
2017-09 31,000 $389,090 0 $0 0 $0
2017-02 0 $0 0 $0 72,666 $0
2016-06 0 $0 1,500 $22,500 1,500 $9,345
2016-05 0 $0 6,000 $78,000 6,000 $37,380
2016-02 0 $0 0 $0 55,147 $0
2015-03 0 $0 0 $0 235,875 $0
2014-12 465,896 $417,254 0 $0 0 $0
2014-11 149,253,731 $149,999,999 0 $0 0 $0
2014-02 0 $0 0 $0 327,250 $0
2013-02 0 $0 0 $0 215,250 $0
2013-01 0 $0 0 $0 192,200 $0
2012-10 6,000,000 $13,500,000 0 $0 0 $0
2012-02 0 $0 0 $0 100,000 $0
2011-12 0 $0 0 $0 78,211 $88,377
2010-03 94,270,206 $108,410,736 0 $0 0 $0
2009-10 15,474,145 $23,212,452 0 $0 0 $0
2008-08 50,824,986 $192,880,821 0 $0 0 $0
2008-04 40,000 $78,720 0 $0 0 $0
2007-12 5,000 $14,900 0 $0 0 $0
2007-06 15,000 $47,850 0 $0 4,000 $10,000
2007-05 0 $0 1,000 $3,400 0 $0
2007-03 0 $0 190,000 $684,000 300,000 $501,000
2007-02 0 $0 52,300 $203,447 90,000 $150,300
2006-08 25,000 $98,175 0 $0 0 $0
2006-04 0 $0 15,000 $76,647 0 $0
2006-03 0 $0 30,000 $165,060 30,000 $75,000
2006-01 0 $0 7,200 $27,360 0 $0
2005-12 0 $0 3,800 $14,060 0 $0
2005-10 1,000 $3,400 0 $0 0 $0
2005-09 1,000 $4,610 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Lexicon Pharmaceuticals, Inc. insiders (LXRX)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-11-17 Invus Public Equities Advisors, Llc (Director) Buy 50,000 9.85 492,500
2017-11-15 Coats Lonnel (President and CEO) Buy 10,000 9.91 99,100
2017-11-15 Invus Public Equities Advisors, Llc (Director) Buy 130,727 10.21 1,334,461
2017-11-14 Invus Public Equities Advisors, Llc (Director) Buy 215,133 9.47 2,037,954
2017-11-14 Wade Jeffrey L (EVP, Corp Adm Affairs and CFO) Buy 2,000 9.48 18,962
2017-11-13 Invus Public Equities Advisors, Llc (Director) Buy 215,133 9.75 2,097,977
2017-11-10 Invus Public Equities Advisors, Llc (Director) Buy 145,680 9.74 1,418,340
2017-09-15 Coats Lonnel (President and CEO) Buy 30,000 12.55 376,590
2017-09-15 Barker Sam L (Director) Buy 1,000 12.50 12,500
2017-02-28 Santini Alexander A (EVP and CCO) Option Ex 2,352 .00 0
2017-02-28 Coats Lonnel (President and CEO) Option Ex 19,226 .00 0
2017-02-28 Lapuerta Pablo (EVP and CMO) Option Ex 14,099 .00 0
2017-02-28 Tessmer James F (VP, Finance & Accounting) Option Ex 6,939 .00 0
2017-02-28 Main Alan J (EVP, CMC and Supply Operations) Option Ex 14,391 .00 0
2017-02-28 Wade Jeffrey L (EVP, Corp Adm Affairs and CFO) Option Ex 15,659 .00 0
2016-06-06 Tessmer James F (VP, Finance & Accounting) Sale 1,500 15.00 22,500
2016-06-06 Tessmer James F (VP, Finance & Accounting) Option Ex 1,500 6.23 9,345
2016-05-23 Tessmer James F (VP, Finance & Accounting) Sale 6,000 13.00 78,000
2016-05-23 Tessmer James F (VP, Finance & Accounting) Option Ex 6,000 6.23 37,380
2016-02-29 Coats Lonnel (President and CEO) Option Ex 10,835 .00 0
2016-02-29 Lapuerta Pablo (EVP and CMO) Option Ex 11,728 .00 0
2016-02-29 Tessmer James F (VP, Finance & Accounting) Option Ex 5,828 .00 0
2016-02-29 Main Alan J (EVP, CMC and Supply Operations) Option Ex 12,807 .00 0
2016-02-29 Wade Jeffrey L (EVP, Corp Adm Affairs and CFO) Option Ex 13,949 .00 0
2015-03-02 Northcott John (VP, Marketing, Comm Strategy) Option Ex 11,250 .00 0
2015-03-02 Lapuerta Pablo (EVP and CMO) Option Ex 50,250 .00 0
2015-03-02 Tessmer James F (VP, Finance & Accounting) Option Ex 29,625 .00 0
2015-03-02 Main Alan J (EVP, CMC and Supply Operations) Option Ex 69,000 .00 0
2015-03-02 Wade Jeffrey L (EVP, Corp Adm Affairs and CFO) Option Ex 75,750 .00 0
2014-12-12 Debbane Raymond (Director) Buy 150,000 .88 132,000
2014-12-10 Debbane Raymond (Director) Buy 315,896 .90 285,254
2014-11-26 Invus Public Equities Advisors, Llc (Director) Buy 149,253,731 1.00 149,999,999
2014-02-28 Lapuerta Pablo (EVP, Clin Dev and CMO) Option Ex 30,500 .00 0
2014-02-28 Tessmer James F (VP, Finance & Accounting) Option Ex 20,250 .00 0
2014-02-28 Main Alan J (EVP, Pharmaceutical Research) Option Ex 50,250 .00 0
2014-02-28 Zambrowicz Brian P (EVP, Chief Scientific Officer) Option Ex 62,750 .00 0
2014-02-28 Wade Jeffrey L (EVP, Corp Dev and CFO) Option Ex 55,250 .00 0
2014-02-28 Sands Arthur T (President & CEO) Option Ex 108,250 .00 0
2013-02-28 Lapuerta Pablo (EVP, Clin Dev and CMO) Option Ex 13,000 .00 0
2013-02-28 Tessmer James F (VP, Finance & Accounting) Option Ex 14,250 .00 0
2013-02-28 Main Alan J (EVP, Pharmaceutical Research) Option Ex 33,750 .00 0
2013-02-28 Zambrowicz Brian P (EVP, Chief Scientific Officer) Option Ex 42,750 .00 0
2013-02-28 Wade Jeffrey L (EVP, Corp Dev and CFO) Option Ex 38,250 .00 0
2013-02-28 Sands Arthur T (President & CEO) Option Ex 73,250 .00 0
2013-01-31 Tessmer James F (VP, Finance & Accounting) Option Ex 13,200 .00 0
2013-01-31 Main Alan J (EVP, Pharmaceutical Research) Option Ex 31,600 .00 0
2013-01-31 Zambrowicz Brian P (EVP, Chief Scientific Officer) Option Ex 42,100 .00 0
2013-01-31 Wade Jeffrey L (EVP, Corp Dev and CFO) Option Ex 31,600 .00 0
2013-01-31 Sands Arthur T (President & CEO) Option Ex 73,700 .00 0
2012-10-23 Minne Pascal (Director) Buy 3,000,000 2.25 6,750,000
2012-10-23 Debbane Raymond (Director) Buy 3,000,000 2.25 6,750,000
2012-02-28 Tessmer James F (VP, Finance & Accounting) Option Ex 7,500 .00 0
2012-02-28 Main Alan J (EVP, Pharmaceutical Research) Option Ex 16,250 .00 0
2012-02-28 Zambrowicz Brian P (EVP, Chief Scientific Officer) Option Ex 21,250 .00 0
2012-02-28 Wade Jeffrey L (EVP, Corp Dev and CFO) Option Ex 18,750 .00 0
2012-02-28 Sands Arthur T (President & CEO) Option Ex 36,250 .00 0
2011-12-22 Main Alan J (EVP, Pharmaceutical Research) Option Ex 19,211 1.13 21,708
2011-12-22 Barker Sam L (Director) Option Ex 34,000 1.13 38,420
2011-12-22 Sands Arthur T (President & CEO) Option Ex 25,000 1.13 28,249
2010-03-19 Debbane Raymond (10% Owner) Buy 94,270,206 1.15 108,410,736
2009-10-22 Barker Sam L Buy 19,000 1.56 29,735
2009-10-15 Debbane Raymond (10% Owner) Buy 2,015,888 1.50 3,023,832
2009-10-14 Debbane Raymond (10% Owner) Buy 13,439,257 1.50 20,158,885
2008-08-23 Debbane Raymond (10% Owner) Buy 50,824,986 3.79 192,880,821
2008-04-18 Barker Sam L (Director) Buy 40,000 1.97 78,720
2007-12-19 Nies Alan S (Director) Buy 5,000 2.98 14,900
2007-06-26 Rose Clayton Stuart (Director) Buy 15,000 3.19 47,850
2007-06-19 Ishimoto Lance K (SVP, Intellectual Property) Option Ex 4,000 2.50 10,000
2007-05-15 Piggott James R Phd (SVP of Pharm Bio) Sale 1,000 3.40 3,400
2007-03-29 Sands Arthur T (Pres & CEO) Sale 190,000 3.60 684,000
2007-03-29 Sands Arthur T (Pres & CEO) Option Ex 300,000 1.67 501,000
2007-02-01 Zambrowicz Brian P (EVP, Research) Sale 52,300 3.89 203,447
2007-02-01 Zambrowicz Brian P (EVP, Research) Option Ex 90,000 1.67 150,300
2006-08-18 Mills Barry (Director) Buy 25,000 3.93 98,175
2006-04-18 Sands Arthur T (Pres & CEO) Sale 11,690 5.10 59,618
2006-04-17 Sands Arthur T (Pres & CEO) Sale 3,310 5.14 17,029
2006-03-23 Piggott James R Phd (SVP of Pharm Bio) Sale 30,000 5.50 165,060
2006-03-23 Piggott James R Phd (SVP of Pharm Bio) Option Ex 30,000 2.50 75,000
2006-01-04 Gregory Julia P (EVP, Corp Dev and CF) Sale 7,200 3.80 27,360
2005-12-30 Gregory Julia P (EVP, Corp Dev and CF) Sale 3,800 3.70 14,060
2005-10-13 Caskey C Thomas (Director) Buy 1,000 3.40 3,400
2005-09-02 Caskey C Thomas (Director) Buy 1,000 4.61 4,610

Insider trading activities including stock purchases, stock sales, and option exercises of LXRX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Lexicon Pharmaceuticals, Inc. (symbol LXRX, CIK number 1062822) see the Securities and Exchange Commission (SEC) website.